Commentary: real-world triple therapy experience treating hepatitis C virus - authors' reply.
Division of Liver Diseases, Icahn School of Medicine at the Mount Sinai Medical Center, New York, NY, USA. kian.bichoupan@mssm.edu.
K
K
Bichoupan
J M
JM
Schwartz
V
V
Martel-Laferriere
E R
ER
Giannattasio
K
K
Marfo
J A
JA
Odin
L U
LU
Liu
T D
TD
Schiano
P
P
Perumalswami
M
M
Bansal
P J
PJ
Gaglio
H
H
Kalia
D T
DT
Dieterich
A D
AD
Branch
J F
JF
Reinus
D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011092:Polyethylene Glycols; D012254:Ribavirin